The acquisition was announced on Monday with James Walker, CEO of Agostini’s Pharmaceutical Group, presents at MDJL’s Carifta ...

For instance, Novo Nordisk’s Rare Disease group ... AstraZeneca’s Alexion, which recently announced the building of a new rare disease development hub in Barcelona, is focused mostly on ...

As I step into Rajeev Juneja’s office at Mankind Pharma’s Delhi headquarters ... Pharma major Novo Nordisk saw a lot of success with their launch of glucagon-like peptide-1 (GLP-1) drugs ...

Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...

Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...

While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the same molecule semaglutide at higher doses than Ozempic ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its popular diabetes and weight loss medicines, including Wegovy and ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... Novo is working on building new manufacturing sites to combat this, and the closing of the Catalent deal at the end of 2024 that ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...